Project description
Faster diagnosis of antimicrobial resistance
The injudicious use of antibiotics has led to the emergence of antimicrobial resistance (AMR) caused by bacteria which cannot be killed by existing drugs. AMR threatens routine hospital-based procedures and leads to a significant number of deaths every year. The aim of the EU-funded Nanosynex project is to put forward a disruptive microfluidic-based technology that significantly cuts down on sample processing time and delivers faster diagnosis of AMR. Introduction of the device into routine diagnostic practice will help clinicians make more informed and accurate decisions on antibiotic therapies to treat their patients.
Objective
Antimicrobial Resistance (AMR) has been declared as one of today’s biggest global threats as 700,000 people die due AMR.
Inappropriate antibiotic use is widespread. In the general practice, physicians commonly use empirical antibiotic therapy (highly inaccurate), since AST results take too long. Nanosynex product provides a revolutionary ultra-fast AST technology that will disrupt the market by cutting time to results in more than half (from 9 – the fastest - to 4 hours). This will allow physicians to get same-day results (i.e. in less than 5 hours) for AST, a unique feature that will save at least one day of hospitalization per patient and help reducing the spread of resistant bacteria. A successful validation through this Phase-1 of the technology and our revenue models will be fundamental to demonstrate evidence of user satisfaction A successful validation through this Phase-1 of the technology and our revenue models will be fundamental to demonstrate evidence of user satisfaction. Nanosynex Ltd is an Israeli start-up providing health-care systems with a rapid microfluidic diagnostic solution for faster and personalised antibiotic treatment. The company intends to scale up in the European market first, thanks to its strategic partnership with Biosynex, a leading French rapid diagnostic test (RDT) company that has an established distribution network in Europe, Middle East and Africa (60+ countries). Afterwards, Nanosynex will expand internationally. Nanosynex forecast to generates 14.7M€ , and and at EBITDA of 3.4M€ by 2024
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- natural sciencesbiological sciencesmicrobiologybacteriology
- social scienceseconomics and businessbusiness and managementbusiness models
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- engineering and technologymedical engineeringmedical laboratory technologydiagnostic technologies
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
You need to log in or register to use this function
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
5126112 Bnei Brak
Israel
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.